Organovo Presents FXR314 3D Human Tissue Model Findings That Show Improved Epithelial Barrier Function and Fibrosis Reduction at Crohn’s and Colitis Congress
- None.
- None.
Insights
The preclinical data presented by Organovo Holdings, Inc. regarding their FXR314 development program is a significant milestone in the field of inflammatory bowel disease (IBD) treatment. The use of proprietary 3D human tissue models for Crohn's disease and ulcerative colitis has potential implications for improving the predictive accuracy of preclinical studies, which has been a longstanding challenge in drug development. These models could potentially bridge the gap between conventional in vitro studies and human clinical trials, offering a more reliable forecast of a drug's efficacy and safety profile.
FXR314's role as a non-bile acid FXR agonist introduces a novel therapeutic approach, diverging from traditional immune response modulation. This could be particularly beneficial for patients who are unresponsive to current treatments. The reported improvements in epithelial barrier function and control of fibrosis suggest that FXR314 may address some of the underlying pathophysiological mechanisms of IBD, which include compromised intestinal barrier integrity and tissue scarring.
Furthermore, the emphasis on FXR314's multifaceted activity profile indicates a comprehensive therapeutic potential beyond symptom management, which could translate into a competitive advantage in the IBD treatment market. However, it is important to remain cautious, as the transition from preclinical to clinical efficacy is not always linear and many compounds fail to replicate early-stage success in later trials.
Organovo’s announcement at the Crohn's and Colitis Congress could have a positive impact on investor sentiment, given that the IBD market is expected to grow due to an increasing prevalence of the disease and the demand for novel treatments. The company's focus on a differentiated mechanism of action for FXR314 positions it to potentially capture a share of this expanding market. The ability to demonstrate efficacy in proprietary 3D human tissue models may also provide Organovo with a strategic edge in attracting partnership opportunities or licensing deals.
However, investors should consider the inherent risks associated with clinical-stage biotech companies, including the possibility of unfavorable clinical trial results, regulatory hurdles and the challenges of commercialization. The positive preclinical data, while promising, does not guarantee successful clinical outcomes and the drug's market potential will ultimately depend on its clinical trial performance, safety profile and the competitive landscape at the time of potential market entry.
Organovo Holdings, Inc.'s presentation of preclinical data is an important event that could influence the company's valuation and stock performance. The development of FXR314 could lead to substantial R&D expenses in the near term, but successful clinical trials might justify these investments through future revenue streams. The drug's progress through the clinical pipeline can trigger milestone payments if Organovo has established partnerships or could enhance the company's attractiveness to potential collaborators.
Investors should monitor subsequent clinical trial phases closely, as these will provide more definitive evidence of FXR314's efficacy and safety. Positive results could lead to an increase in Organovo's stock price, while any setbacks might have the opposite effect. It is also crucial to analyze Organovo's financial health, including cash burn rate and capital-raising activities, as these will determine the company's ability to sustain its development efforts through to commercialization.
SAN DIEGO, Jan. 25, 2024 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq: ONVO), a clinical stage biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis, based on demonstration of clinical promise in three-dimensional (3D) human tissues, today announced the presentation of preclinical data related to the company’s FXR314 development program in its proprietary 3D human tissue models of Crohn’s disease and ulcerative colitis at the Crohn’s and Colitis Congress being held January 25-27, 2024 in Las Vegas, Nevada.
FXR314 is a clinical-stage potent, selective, orally administered non-bile acid FXR agonist being developed as a novel therapeutic approach for IBD.
“There is a critical need for novel approaches to treat inflammatory bowel disease (IBD) that extend beyond modulating the immune response targeted by current pharmacological therapies. These data underscore the potential of FXR314 as a unique treatment approach to IBD given its demonstrated multifaceted activity profile, especially in directly improving the intestinal barrier function and controlling fibrosis,” said Dr. Fabrice Piu, Vice President, Research & Development. “The Crohn’s and Colitis Congress is a unique opportunity to demonstrate this potential among key thought leaders in the field and as we continue to drive our program forward.”
The presentation highlights preclinical data characterizing the activity of FXR314 in 3D models of human Crohn’s disease and ulcerative colitis. FXR314 broadly improved measures of epithelial barrier function in a subset of donors, and fibrotic markers in all Crohn’s disease donors. In ulcerative colitis, FXR314 improved epithelial barrier function and fibrotic activity in all donors.
“Organovo’s primary multicellular 3D human IBD models constitute a powerful tool to more accurately predict the relevance of specific targets and assess the efficacy of therapeutic candidates. We strongly believe these results increase the probability of success with FXR314 when conducting IBD clinical trials, due to its demonstrated comparability to known disease,” added Keith Murphy, Organovo’s Executive Chairman.
Organovo’s current development program for FXR314 focuses on inflammatory bowel disease, where the drug’s differentiated mechanism of action, as highlighted in Organovo’s recently provided mechanism of action video at https://organovo.com/about/, provides substantial promise that the drug’s impact will strongly complement the biology of other successful drugs in ulcerative colitis and Crohn’s disease. Organovo plans to begin enrollment for a proof-of-concept Phase 2 ulcerative colitis study in 2024, with targeted completion in 2025. The drug’s additional promise in liver fibrosis and NASH makes it a strong candidate for development in that.
Details of the presentation at the Crohn’s and Colitis Congress in Las Vegas are shown below:
| Title: | Evaluation of the clinical stage FXR agonist FXR314 in human primary cell 3D models of Crohn’s disease and ulcerative colitis | |
| Presenter: | Dr. Fabrice Piu, Vice President Research & Development | |
| Date: | Friday January 26, 2024 at 3 PM (Pacific) | |
About Organovo
Organovo is a clinical stage biotechnology company that is developing drugs that are demonstrated to be effective in three-dimensional (3D) human tissues as candidates for drug development. The company’s lead molecule, FXR314, is on the path for Phase 2 investigation in inflammatory bowel disease and has potential application in metabolic liver disease and oncology. The company has proprietary technology used to build 3D human tissues that mimic key aspects of native human tissue composition, architecture, function and disease. For more information visit Organovo's website at www.organovo.com.
Forward Looking Statements
Any statements contained in this press release that do not describe historical facts constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. These risks and uncertainties and other factors are identified and described in more detail in the Company’s filings with the SEC, including its Annual Report on Form 10-K filed with the SEC on July 14, 2023, as such risk factors are updated in its most recently filed Quarterly Report on Form 10-Q filed with the SEC on November 9, 2023. You should not place undue reliance on these forward-looking statements, which speak only as of the date that they were made. These cautionary statements should be considered with any written or oral forward-looking statements that the Company may issue in the future. Except as required by applicable law, including the securities laws of the United States, the Company does not intend to update any of the forward-looking statements to conform these statements to reflect actual results, later events or circumstances or to reflect the occurrence of unanticipated events.
Contact
Core Investor Relations
pr@coreir.com
FAQ
What did Organovo present at the Crohn’s and Colitis Congress?
What is the focus of Organovo's current development program for FXR314?
What are the potential benefits of FXR314 for IBD treatment?
